Office-based Validation of the JVPHome

Sponsor
Eastern Regional Health Authority (Other)
Overall Status
Recruiting
CT.gov ID
NCT05193864
Collaborator
JVPLabs (Other)
60
1
13.1
4.6

Study Details

Study Description

Brief Summary

The JVPHome is a novel medical device that utilizes machine vision in order to facilitate assessment of jugular venous pressure (JVP) height relative to the sternal angle with the ultimate goal of enabling remote JVP monitoring. The current study aims to evaluate the ability of an enhanced version of the JVPHome to enable remote identification of JVP height relative to ultrasound among congestive heart failure (CHF) patients when the device is applied by the study team in the clinic.

Condition or Disease Intervention/Treatment Phase
  • Device: Device: JVPHome and ultrasound

Detailed Description

CHF is a common and devastating health problem estimated to affect upwards of 26 million individuals worldwide. Following an initial hospitalization for heart failure, approximately 25% of patients are readmitted within the first 30 days of discharge. Repeat heart failure hospitalizations are a major burden on both patients and healthcare systems. To date, there is an absence of non-invasive solutions proven to reduce the risk of re-hospitalization for CHF.

The key feature of the physical examination for assessing the volume status of CHF patients is the JVP, which manifests as a biphasic pulsation along the neck. The height of the JVP relative to the sternal angle is a reflection of right atrial pressure, which increases in response to higher pressures transmitted from the left side of the heart. Pathologic elevation of left sided heart pressures can result in fluid congestion in the lungs, which can cause patients to develop shortness of breath and reduced blood oxygen levels. Although a crucial marker of volume status, accurate identification of the JVP can be challenging for physicians due to its pulsations often being subtle.

The JVPHome is a novel medical device designed to facilitate visualization of JVP height relative to the sternal angle through the use of machine vision. The current study aims to evaluate an enhanced version of the JVPHome in a clinic setting when the device is applied to CHF patients by clinicians. Following its application, the JVPHome will be allowed to record a video of the JVP and images will subsequently be transmitted to a secure cloud and undergo analysis with machine vision software. Visualization of the JVP will be facilitated through simultaneous electrocardiographic and pulse oximetry recordings by the JVPHome. Following its application, data is transferred to a secure cloud server for subsequent processing and clinical review.

JVP height of study participants will be concurrently assessed through the use of ultrasound (gold standard). Clinicians that are blinded to ultrasound determined JVP height values will assess JVP height generated by the JVPHome. Analyses will then assess the accuracy of the JVPHome relative to ultrasound and expert clinical assessment.

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Office-based Validation of the JVPHome
Actual Study Start Date :
Nov 29, 2021
Anticipated Primary Completion Date :
Nov 3, 2022
Anticipated Study Completion Date :
Jan 3, 2023

Arms and Interventions

Arm Intervention/Treatment
Ambulatory CHF patients

Patients visiting an outpatient CHF clinic

Device: Device: JVPHome and ultrasound
Remote clinician assessment of JVP height using the JVPHome, and ultrasound based assessment of JVP height in the same patients.

Outcome Measures

Primary Outcome Measures

  1. Accuracy of JVP assessment using the JVPHome [Day 1]

    Correlation between JVP height assessed by JVPHome and ultrasound Correlation between JVP height assessed by JVPHome and ultrasound Correlation between JVP height assessed by JVPHome and ultrasound

Secondary Outcome Measures

  1. Electrocardiographic Assessment [Day 1]

    Evaluate the ability of an embedded ECG sensor to generate a quality single-lead ECG sufficient to identify heart rhythm.

  2. Pulse Oximetry Assessment [Day 1]

    Evaluate the ability of an embedded PPG sensor to generate a quality PPG signal in-clinic.

  3. Respiratory Rate [Day 1]

    Validate the ability of the JVPHome to measure respiratory rate and compare to expert clinical assessment.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Age >/= 18 years

  • Congestive heart failure diagnosis receiving ongoing treatment

  • Able to provide informed consent

Exclusion Criteria:
  • Conditions which preclude visualization of the JVP, including neck deformity, scarring, and facial hair

Contacts and Locations

Locations

Site City State Country Postal Code
1 Eastern Health St. John's Newfoundland and Labrador Canada A1B 2X5

Sponsors and Collaborators

  • Eastern Regional Health Authority
  • JVPLabs

Investigators

  • Principal Investigator: Kris Aubrey-Bassler, MD, Eastern Health

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Eastern Regional Health Authority
ClinicalTrials.gov Identifier:
NCT05193864
Other Study ID Numbers:
  • 335576
First Posted:
Jan 18, 2022
Last Update Posted:
Jul 28, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Eastern Regional Health Authority
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 28, 2022